Search

Support opportunities

View the EHA Ranking for 2025

EHA thrives on the support of the biomedical industry and the medical profession. The variety of opportunities available for industry range from educational activities to the EHA Congress.

Read more

EHA Innovation Grant review and selection process

1. Eligibility checkAfter the deadline has passed, we'll check your application for completion and compliance with the eligibility criteria.

Read more

EHA policy on double awarding

EHA is guided by the concept of supporting as many young investigators/clinicians as possible in their career development. Therefore, double awarding is not allowed. Winning an award excludes the award winner from winning another award while receiving the first.

Read more

EHA-ISHBT Hematology Tutorial on Hematological Disorders

Dates: February 28-29, 2020
Location: Chandigarh, India
Chairs: N Varma, P Malhotra, J Gribben

Organized by: European Hematology Association (EHA) & Indian Society of Hematology and Blood Transfusion (ISHBT)

EHA will join ISHBT for a fourth time to organize the EHA-ISHBT Hematology Tutorial, this time in Chandigargh,…

Read more

Hematology and oncology, pacemakers for EU HTA

EHA’s Martin Kaiser, right, addressing his fellow panelists. Left to right: Brian Cuffel (Bayer), Caroline Pothet (EMA), Roisin Adams (HTA CG), Bernhard Wörmann (DGHO) and Elisabeth de Vries (ESMO).

Read more

T2EVOLVE: breakthrough alliance boosting Europe to the forefront of cancer immunotherapy

This press release is originally found here: http://prn. to/2YF7Js3

THE HAGUE, Netherlands, Feb. 3, 2021 /PRNewswire/ -- T2EVOLVE is a new breakthrough alliance of academic and industry leaders in cancer immunotherapy under the European Union's Innovative Medicines Initiative (IMI).

Read more

A new targeted combination therapy with potential to eliminate relapsed chronic lymphocytic leukemia

Patients with chronic lymphocytic leukemia (CLL) that has recurred or isn’t responding to standard treatment need new therapies. A new combination of two targeted therapies is showing potential to eliminate CLL in these circumstances.

Read more